The Neurology Clinical Trials Unit at Massachusetts General Hospital has been awarded an $80,000 grant to create a data management center for a clinical trial of Coenzyme Q10, a compound designed to battle Amyotrophic Lateral Sclerosis (Lou Gehrig's disease).

Making the grant was the ALS Therapy Development Foundation in Newton.
The grant funds the development of a data management center to organize and collect data for an upcoming Phase I trial of Coenzyme Q10, one of several compounds that ALS-TDF has prioritized for further clinical testing in ALS.

ALS is a fatal disorder that causes paralysis through the progressive death of motor neurons. About 30,000 Americans have ALS.

The ALS Therapy Development Foundation (www.als.net), founded in 1999, has collaborated with 28 nonprofit companies and academic institutions in seeking drug candidates to fight the disease.